DelveInsight’s, “Ocular Hypertension Pipeline Insight 2023” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Ocular Hypertension Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key Takeaways from the Ocular Hypertension Pipeline Report
To explore more information on the latest breakthroughs in the Ocular Hypertension Pipeline treatment landscape of the report, click here @ Ocular Hypertension Pipeline Outlook
Ocular Hypertension Overview
Ocular hypertension occurs when the pressure inside the eye exceeds the range considered normal and goes higher than 21 mm Hg. The increase in intraocular pressure (progressive with age, although may also be due to other disorders or causes) is the main risk factor for developing glaucoma and, therefore, people with ocular hypertension are more likely to suffer the disease.
Recent Developmental Activities in the Ocular Hypertension Treatment Landscape
For further information, refer to the detailed Ocular Hypertension Unmet Needs, M Ocular Hypertension Market Drivers, and Ocular Hypertension Market Barriers, click here for Ocular Hypertension Ongoing Clinical Trial Analysis
Ocular Hypertension Emerging Drugs Profile
NCX 470, is a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in Phase III clinical development for the lowering of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.
It is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. It is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension.
QLS-101 is an investigational therapy, designed to lower intraocular pressure (IOP) by reducing episcleral venous pressure (EVP) in individuals with glaucoma. It is currently in Phase II trial in adolescents with Sturge-Weber syndrome (SWS) who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least one eye.
It is a novel adenosine triphosphate (ATP)-sensitive potassium (KATP) channel modulator administered as a topical eyedrop. Beyond its potential utility as an effective monotherapy or additive therapy for the lowering of IOP in primary open angle glaucoma (POAG), QLS-101 may represent a new treatment paradigm in additional populations where current IOP-lowering therapies are inadequate, including normal-tension glaucoma (NTG) and patients with Sturge-Weber syndrome (SWS, a rare pediatric disease).
TO-O-1001 (Formerly known as MG-O-1001) eye drops is a patented new generation Rho kinase (ROCK) inhibitor for treating patients with primary open-angle glaucoma or ocular hypertension. Its therapeutic potency is established through a dual-targeting mechanism, which in turn leads to relaxation of the cells of trabecular meshwork and the inner walls of Schlemm’s canal. It is currently in Phase I/II for Patients with Open-Angle Glaucoma or Ocular Hypertension.
Its unique features include novel and proven working mechanism, good for used alone or in combination with the other IOP-lowering agents, best in class as the ROCK inhibition is a proven clinical approach for lowering IOP, animal studies showed superior efficacy results in IOP-lowering than the current market leader, and user-friendly as once a day.
Ocular Hypertension Pipeline Therapeutics Assessment
There are approx. 70+ key companies which are developing the therapies for Ocular Hypertension. The companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.
Request a sample and discover the recent advances in Ocular Hypertension Ongoing Clinical Trial Analysis and Medications, click here @ Ocular Hypertension Treatment Landscape
Scope of the Ocular Hypertension Pipeline Report
Dive deep into rich insights for drugs for Ocular Hypertension Market Drivers and Ocular Hypertension Market Barriers, click here @ Ocular Hypertension Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Ocular Hypertension Mergers and acquisitions, Ocular Hypertension Licensing Activities @ Ocular Hypertension Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
